{"component": "definition", "props": {"groups": [{"samples": [{"hash": "lyZ5Ace66ob", "uri": "/contracts/lyZ5Ace66ob#performance-milestone", "label": "Exclusive Patent License Agreement (Cellectis S.A.)", "score": 31.9924716949, "published": true}, {"hash": "gGPkxgB372O", "uri": "/contracts/gGPkxgB372O#performance-milestone", "label": "Exclusive Patent License Agreement (Acutus Medical, Inc.)", "score": 31.5352497101, "published": true}, {"hash": "aHwKXUisx14", "uri": "/contracts/aHwKXUisx14#performance-milestone", "label": "Exclusive Patent License Agreement (Acutus Medical, Inc.)", "score": 31.3682403564, "published": true}], "snippet": "means an act or event specified in section 5.1 and described in section 9 of the EPLA.", "snippet_links": [{"key": "an-act", "type": "definition", "offset": [6, 12]}, {"key": "section-51", "type": "clause", "offset": [35, 46]}, {"key": "section-9", "type": "definition", "offset": [64, 73]}], "size": 19, "hash": "f8a9b8416a1bcd39c12f4b498bcd7d78", "id": 1}, {"samples": [{"hash": "iIGdVroTwOZ", "uri": "/contracts/iIGdVroTwOZ#performance-milestone", "label": "Exclusive Start Up License Agreement (Sana Biotechnology, Inc.)", "score": 32.0335388184, "published": true}, {"hash": "2JV78HZvo7r", "uri": "/contracts/2JV78HZvo7r#performance-milestone", "label": "Exclusive Start Up License Agreement (Global Cancer Technology, Inc.)", "score": 29.7857627869, "published": true}, {"hash": "4O7GIuNZDYy", "uri": "/contracts/4O7GIuNZDYy#performance-milestone", "label": "Exclusive License Agreement", "score": 27.2012329102, "published": true}], "snippet": "means any of the milestones described in Section A2 (Performance Milestones) of attached Exhibit A (Start-Up License Schedule).", "snippet_links": [{"key": "the-milestones", "type": "clause", "offset": [13, 27]}, {"key": "performance-milestones", "type": "clause", "offset": [53, 75]}, {"key": "exhibit-a", "type": "definition", "offset": [89, 98]}, {"key": "license-schedule", "type": "definition", "offset": [109, 125]}], "size": 17, "hash": "446d47197d6f7c7a96bc108dbf72eddb", "id": 2}, {"samples": [{"hash": "lBEppjhIF0s", "uri": "/contracts/lBEppjhIF0s#performance-milestone", "label": "Software License Agreement", "score": 34.446018219, "published": true}, {"hash": "egcOx9kGBdi", "uri": "/contracts/egcOx9kGBdi#performance-milestone", "label": "Exclusive License Agreement (Finch Therapeutics Group, Inc.)", "score": 33.2436676025, "published": true}, {"hash": "fB6boVXbXgG", "uri": "/contracts/fB6boVXbXgG#performance-milestone", "label": "Exclusive License Agreement", "score": 26.4236831665, "published": true}], "snippet": "means an act or event specified described in Section 9 of the Business Terms.", "snippet_links": [{"key": "an-act", "type": "definition", "offset": [6, 12]}, {"key": "section-9", "type": "definition", "offset": [45, 54]}, {"key": "business-terms", "type": "definition", "offset": [62, 76]}], "size": 13, "hash": "5aef0ad4a0e48bc7d6fe9dbbe01d3e00", "id": 3}, {"samples": [{"hash": "5W0z7kQs9jC", "uri": "/contracts/5W0z7kQs9jC#performance-milestone", "label": "Exclusive Patent License Agreement (Finch Therapeutics Group, Inc.)", "score": 32.1540031433, "published": true}, {"hash": "lc39WqLMATv", "uri": "/contracts/lc39WqLMATv#performance-milestone", "label": "Exclusive Patent License Agreement (Finch Therapeutics Group, Inc.)", "score": 32.107460022, "published": true}], "snippet": "means an act or event specified in section 5.1 of these Terms and Conditions and described in section 9 of the Key Details.", "snippet_links": [{"key": "an-act", "type": "definition", "offset": [6, 12]}, {"key": "section-51", "type": "clause", "offset": [35, 46]}, {"key": "these-terms-and-conditions", "type": "clause", "offset": [50, 76]}, {"key": "section-9", "type": "definition", "offset": [94, 103]}, {"key": "key-details", "type": "clause", "offset": [111, 122]}], "size": 9, "hash": "3d30df603ae8bf764aee72e5f97bad15", "id": 4}, {"samples": [{"hash": "c10Er9vf2Fv", "uri": "/contracts/c10Er9vf2Fv#performance-milestone", "label": "Low Carbon Inertia Service Agreement", "score": 32.6704139709, "published": true}, {"hash": "cX6FDLUb7er", "uri": "/contracts/cX6FDLUb7er#performance-milestone", "label": "Low Carbon Inertia Service Agreement", "score": 32.3145561218, "published": true}, {"hash": "25RxAImeiNz", "uri": "/contracts/25RxAImeiNz#performance-milestone", "label": "Ds3 System Services Fixed Contracts Agreement", "score": 28.4220199585, "published": true}], "snippet": "means a development milestone of the Providing Unit as set out in Schedule 4;", "snippet_links": [{"key": "development-milestone", "type": "clause", "offset": [8, 29]}, {"key": "providing-unit", "type": "definition", "offset": [37, 51]}, {"key": "set-out", "type": "definition", "offset": [55, 62]}, {"key": "schedule-4", "type": "clause", "offset": [66, 76]}], "size": 8, "hash": "e3090f53530c305899f6b26276bcdfec", "id": 5}, {"samples": [{"hash": "5JtVmM4aCpe", "uri": "/contracts/5JtVmM4aCpe#performance-milestone", "label": "Loan and Security Agreement", "score": 31.3408622742, "published": true}, {"hash": "biU1GumVmxX", "uri": "/contracts/biU1GumVmxX#performance-milestone", "label": "Loan and Security Agreement (Constellation Pharmaceuticals Inc)", "score": 30.2156066895, "published": true}, {"hash": "58gvTtWLZ6p", "uri": "http://ir.constellationpharma.com/static-files/79903fef-2c49-469b-8986-f310a63ec604", "label": "ir.constellationpharma.com", "score": 10.1704311371, "published": false}], "snippet": "means satisfaction of each of the following events: (a) no default or Event of Default shall have occurred and be continuing; and (b) Borrower shall have received after the Closing Date and on or prior to March 31, 2020, an amount equal to at least Fifty Million Dollars ($50,000,000) in unrestricted (including, not subject to any redemption, clawback, escrow or similar encumbrance or restriction other than in the case the Permitted Convertible Debt Financing) net cash proceeds from one or more bona fide equity financings, Subordinated Indebtedness (which, for the avoidance of doubt, may include the net proceeds received from any Permitted Convertible Debt Financing) and/or upfront or other milestone proceeds from business development transactions permitted under this Agreement, in each case subject to verification by Agent (including supporting documentation reasonably requested by Agent).", "snippet_links": [{"key": "satisfaction-of", "type": "clause", "offset": [6, 21]}, {"key": "default-shall", "type": "definition", "offset": [79, 92]}, {"key": "borrower-shall", "type": "clause", "offset": [134, 148]}, {"key": "after-the-closing-date", "type": "clause", "offset": [163, 185]}, {"key": "prior-to", "type": "clause", "offset": [196, 204]}, {"key": "equal-to", "type": "definition", "offset": [231, 239]}, {"key": "subject-to", "type": "clause", "offset": [317, 327]}, {"key": "in-the-case", "type": "clause", "offset": [410, 421]}, {"key": "permitted-convertible-debt-financing", "type": "definition", "offset": [426, 462]}, {"key": "net-cash-proceeds", "type": "definition", "offset": [464, 481]}, {"key": "bona-fide", "type": "clause", "offset": [499, 508]}, {"key": "equity-financings", "type": "clause", "offset": [509, 526]}, {"key": "subordinated-indebtedness", "type": "clause", "offset": [528, 553]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [562, 588]}, {"key": "net-proceeds", "type": "definition", "offset": [606, 618]}, {"key": "transactions-permitted", "type": "clause", "offset": [744, 766]}, {"key": "this-agreement", "type": "clause", "offset": [773, 787]}, {"key": "each-case", "type": "definition", "offset": [792, 801]}, {"key": "by-agent", "type": "clause", "offset": [826, 834]}, {"key": "supporting-documentation", "type": "clause", "offset": [846, 870]}, {"key": "requested-by", "type": "clause", "offset": [882, 894]}], "size": 5, "hash": "3f48f77d2443ba08cde2661195f3a510", "id": 6}, {"samples": [{"hash": "ln5nYUVzp04", "uri": "/contracts/ln5nYUVzp04#performance-milestone", "label": "Loan and Security Agreement (Tricida, Inc.)", "score": 29.421628952, "published": true}, {"hash": "dgPNUK6PRei", "uri": "/contracts/dgPNUK6PRei#performance-milestone", "label": "Loan and Security Agreement (Tricida, Inc.)", "score": 29.3641338348, "published": true}], "snippet": "means, satisfaction of each of the following events: (a) no Event of Default shall have occurred and be continuing and (b) on or before December 15, 2018, or such later date as Agent agrees in writing in its sole discretion, Borrower shall have achieved positive clinical data from the Phase 3 trial of TRC101 and shall provide supporting documentation relating to the results of the trial as and when reasonably requested by Agent.", "snippet_links": [{"key": "satisfaction-of", "type": "clause", "offset": [7, 22]}, {"key": "default-shall", "type": "definition", "offset": [69, 82]}, {"key": "before-december", "type": "clause", "offset": [129, 144]}, {"key": "agent-agrees", "type": "clause", "offset": [177, 189]}, {"key": "in-writing", "type": "definition", "offset": [190, 200]}, {"key": "sole-discretion", "type": "clause", "offset": [208, 223]}, {"key": "borrower-shall", "type": "clause", "offset": [225, 239]}, {"key": "clinical-data", "type": "clause", "offset": [263, 276]}, {"key": "phase-3-trial", "type": "definition", "offset": [286, 299]}, {"key": "supporting-documentation", "type": "clause", "offset": [328, 352]}, {"key": "relating-to", "type": "definition", "offset": [353, 364]}, {"key": "the-trial", "type": "clause", "offset": [380, 389]}, {"key": "by-agent", "type": "clause", "offset": [423, 431]}], "size": 5, "hash": "9736dfe62d2ab460dc7f3de83b1d47e0", "id": 7}, {"samples": [{"hash": "UspYc1o2y4", "uri": "/contracts/UspYc1o2y4#performance-milestone", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.7323741913, "published": true}, {"hash": "kMr3tDrJAey", "uri": "/contracts/kMr3tDrJAey#performance-milestone", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.6557159424, "published": true}, {"hash": "eBewJuh4R2D", "uri": "/contracts/eBewJuh4R2D#performance-milestone", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.5544147491, "published": true}], "snippet": "has the meaning set forth in Section 8.3.", "snippet_links": [{"key": "section-83", "type": "clause", "offset": [29, 40]}], "size": 4, "hash": "b88d52cfab8c9d9f03899bbf8132bec8", "id": 8}, {"samples": [{"hash": "lBNFqZWaDwg", "uri": "https://www.sec.gov/Archives/edgar/data/1084755/000119312507022540/dex1042.htm", "label": "Ariba Inc", "score": 2.0, "published": false}, {"hash": "6wnp4PZZYY0", "uri": "https://www.sec.gov/Archives/edgar/data/1084755/000119312507022540/dex1039.htm", "label": "Ariba Inc", "score": 2.0, "published": false}], "snippet": "means the close of the first period of four consecutive fiscal quarters in which the Company recognizes at least $[*****] in subscription software revenue (as determined in accordance with United States Generally Accepted Accounting Principles), provided that the Performance Milestone must be achieved on or before September 30, 2008.", "snippet_links": [{"key": "period-of", "type": "definition", "offset": [29, 38]}, {"key": "fiscal-quarters", "type": "definition", "offset": [56, 71]}, {"key": "the-company-recognizes", "type": "clause", "offset": [81, 103]}, {"key": "software-revenue", "type": "definition", "offset": [138, 154]}, {"key": "in-accordance-with", "type": "clause", "offset": [170, 188]}, {"key": "united-states", "type": "clause", "offset": [189, 202]}, {"key": "generally-accepted-accounting-principles", "type": "clause", "offset": [203, 243]}, {"key": "provided-that", "type": "clause", "offset": [246, 259]}, {"key": "the-performance", "type": "clause", "offset": [260, 275]}], "size": 4, "hash": "c4abaf2e02d6ec88ab075aba3a14efbd", "id": 9}, {"samples": [{"hash": "pNp268Iyba", "uri": "https://www.sec.gov/Archives/edgar/data/72333/000095012309012544/v52663exv10w6.htm", "label": "Bonus Plan (Nordstrom Inc)", "score": 9.0, "published": false}, {"hash": "8aIjvs5MtxJ", "uri": "https://press.nordstrom.com/static-files/3c06a745-37c4-4081-a549-b5f2fa7f8ec5", "label": "press.nordstrom.com", "score": 7.4791240692, "published": false}], "snippet": "means an objective level of performance with respect to a Performance Measure, the achievement of which may determine the degree of payout of a Performance Bonus Award.", "snippet_links": [{"key": "level-of-performance", "type": "clause", "offset": [19, 39]}, {"key": "with-respect-to", "type": "clause", "offset": [40, 55]}, {"key": "performance-measure", "type": "definition", "offset": [58, 77]}, {"key": "determine-the", "type": "clause", "offset": [108, 121]}, {"key": "payout-of", "type": "clause", "offset": [132, 141]}, {"key": "performance-bonus-award", "type": "definition", "offset": [144, 167]}], "size": 4, "hash": "0637b7ed19360660e1d2df5a033045ff", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIecGVyZm9ybWFuY2UtbWlsZXN0b25lIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means an act or event specified in section 5.1 and described in section 9 of the EPLA.", "size": 198, "title": "Performance Milestone", "id": "performance-milestone", "examples": ["Fourth quarter Bonuses and Bonuses calculated on the basis of partial <strong>Performance Milestone</strong> satisfaction shall be paid within 75 days of fiscal year-end.", "Unless an extension is provided due to an Event of Force Majeure during the term of this Agreement, Company shall perform, or shall cause to happen or be performed, the <strong>Performance Milestones</strong> in accordance with the <strong>Performance Milestone</strong> Dates.", "Upon the occurrence of an Event of Force Majeure, the <strong>Performance Milestones</strong> and <strong>Performance Milestone</strong> Dates shall be equitably adjusted to accommodate the Event of Force Majeure.", "When Recipient misses or anticipates missing a <strong>Performance Milestone</strong> deadline, Recipient shall notify the Department in writing as soon as is reasonably practicable.", "In this notification, Recipient shall explain why the deadline has been or will likely be missed; provide a status update relative to the other <strong>Performance Milestone</strong> deadlines; and provide assurances that it will meet the remaining <strong>Performance Milestone</strong> deadlines.", "If ICF withdraws potential Incentive Payments it may, in its sole discretion, allow Homebuilder to reclaim a portion of any withdrawn Incentive Payments if Homebuilder exceeds future <strong>Performance Milestone</strong> Date Requirements.", "Homebuilder also agrees to provide ICF with a list of eligible homes and planned communities during each <strong>Performance Milestone</strong>.", "Fourth quarter Bonuses, Bonuses calculated on the basis of partial <strong>Performance Milestone</strong> satisfaction and Bonuses based upon annual milestones shall be paid by March 15 of the following year.", "These stock options shall be granted as of the end of the quarter in which the <strong>Performance Milestone</strong> is achieved.", "If Company determines that it will be unable to achieve a <strong>Performance Milestone</strong>, Company will so notify University in advance of the <strong>Performance Milestone</strong> Date, and, providing Company demonstrates it is diligently pursuing commercialization of at least one Licensed Product, the Parties will negotiate an appropriate new <strong>Performance Milestone</strong> and/or related <strong>Performance Milestone</strong> Date in good faith."], "related": [["performance-target", "Performance Target", "Performance Target"], ["performance-targets", "Performance Targets", "Performance Targets"], ["performance-objective", "Performance Objective", "Performance Objective"], ["milestone-2", "Milestone 2", "Milestone 2"], ["performance-metrics", "Performance Metrics", "Performance Metrics"]], "related_snippets": [], "updated": "2025-11-08T04:50:29+00:00"}, "json": true, "cursor": ""}}